The size of the North America Cell Fractionation Market was valued at USD 1.00 Billion in 2022. It is further estimated to be growing at a CAGR of 10.65% and worth USD 1.65 billion by 2027.
The demand for cell fractionation increases as the number of cultured cells processed for commercially diagnostic advancements in various equipment and reagents and research purposes grows. The need for pure cellular fractions has prompted the development of novel methods, allowing participants in the cell fractionation market to broaden their options. There is already a wide range of technologies available on the market that would enable end-users to perform cell fractionation on a macro and micro scale. The microelectronic industry's use of microfabrication has set the tone for the present wave of product innovation in the cell fractionation sector. The rise of the North America Cell Fractionation Market is attributable to factors such as expansion in biopharmaceutical firms, which would also provide new development prospects for the market, as cell lysis and interruption are involved in the recovery and refinement biopharmaceuticals.
Furthermore, the market is expected to be driven by the adoption of biotech measures in drugs, agriculture, Increased investments in R&D connected to biotechnological processes by various government and business entities, and academia and bio-services companies. In addition, the increased frequency of chronic diseases, advances in research infrastructure, and favorable regulations for cell-based research to create novel products all have the potential to augment market growth. The instruments can lyse cells with a high yield, maximize active compounds, ensure easy scaling, and are simple to clean. The demand for devices used in cell fractionation operations has surged as a result of these benefits.
The high cost of cell-based research and development, which is essential for introducing innovative goods to the market, limited reimbursement of plasma products, and the growing usage of recombinant alternatives, are estimated to be restricting the market's growth.
This research report has been segmented and sub-segmented the North America Cell Fractionation Market into the following categories.
By Cell Type:
By End User:
Geographically, the North American region is one where the cell fractionation market has seen a lot of activity. The regional market has experienced a tremendous increase in research on generating novel lysis methods about the launch of new equipment and reagents. Growth in the North American region is fueled mainly by factors such as an aging population and increased government investment in the region's governments. In addition, the rising prevalence and rates of numerous diseases and rising research and development expenditures in the North American area are driving the demand for an advanced R&D scenario across all life sciences industries. As a result, the continual expansion of healthcare infrastructure in the United States and an increase in the patient population provide more opportunities for clinical laboratories to expand, aiding the market growth. In addition, the growing demand for cell-based therapy in cancer treatment is projected to boost the cell fractionation market's growth. The most frequent cancers worldwide were discovered to be lung and breast cancers. Furthermore, as the prevalence of infectious diseases and malignancies rises, cell samples are increasingly being used in medication research and development, resulting in favorable growth for the cell fractionation market in the North American region.
KEY MARKET PLAYERS:
Companies playing a promising role in the North American cell fractionation market profiled in the report are Beckman Coulter, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., F. Hoffman-La Roche AG, Merck KGaA, Miltenyi Biotec, QIAGEN N., Qsonica and Thermo Fisher Scientific Inc.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com